Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENZALUTAMIDE vs NUBEQA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.
Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.
Treatment of metastatic castration-resistant prostate cancer,Treatment of metastatic castration-sensitive prostate cancer
Treatment of patients with non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of patients with metastatic hormone-sensitive prostate cancer (m HSPC) in combination with docetaxel
160 mg orally once daily
600 mg orally twice daily with food.
Terminal elimination half-life is approximately 5.8 days (range 2.8–10.2 days) after steady state; supports once-daily dosing.
Terminal elimination half-life is approximately 20 hours; supports once-daily dosing.
Primarily metabolized by CYP2C8 and CYP3A4; forms active metabolite N-desmethyl enzalutamide
Primarily metabolized by CYP3A4 and also by CYP2C8 and UGT1A1 to a lesser extent.
Primarily hepatic metabolism; ~70% of dose excreted in feces (as unchanged drug and metabolites), ~1% in urine as unchanged drug. Biliary excretion is a major route.
Primarily excreted as unchanged drug via feces (approximately 63.7%) and urine (approximately 23.8%); minimal biliary excretion.
97–98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 97% bound to plasma proteins (primarily albumin).
Approximately 110 L (1.1 L/kg for a 70 kg patient); indicates extensive extravascular distribution.
Apparent volume of distribution is approximately 98 L (1.2 L/kg for a 80 kg patient), indicating extensive tissue distribution.
Oral bioavailability is not published; absorption is at least moderate based on systemic exposure. Food does not significantly affect absorption.
Absolute oral bioavailability is approximately 21% (fasted state); increased by 2.6-fold with a high-fat meal.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). Insufficient data for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No dose adjustment for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B): reduce dose to 80 mg once daily. Not recommended for severe (Child-Pugh C).
Child-Pugh A: No adjustment. Child-Pugh B: Not recommended. Child-Pugh C: Contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established; no recommended dose.
No specific dose adjustment required; elderly patients may be more susceptible to adverse effects such as falls, fractures, and hypertension. Monitor closely.
No dose adjustment required based on age alone; monitor for adverse effects.
None
None.
Seizure risk,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions including angioedema,Increased risk of falls and fractures,Embryo-fetal toxicity
Ischemic cardiovascular events,Hypertension,Fractures,Seizures,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions,Fetal toxicity
Pregnancy,Concomitant use with strong CYP2C8 inhibitors or inducers,Concomitant use with strong CYP3A4 inducers
Pregnancy,Severe hepatic impairment (Child-Pugh C)
No significant food interactions. Avoid grapefruit juice as it may increase enzalutamide levels (minor interaction). Take with or without food.
Take with food to increase absorption; food with moderate-to-high fat content enhances bioavailability. Avoid grapefruit juice or products containing grapefruit as they may inhibit P-gp and increase darolutamide levels.
Enzalutamide is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibitor), there is a high risk of fetal harm, particularly male pseudohermaphroditism and impaired reproductive development. Use should be avoided in all trimesters. Women of childbearing potential must use effective contraception during treatment and for 1 month after the last dose.
NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse developmental effects including embryotoxicity and malformations in rats at exposures below human clinical exposure. No adequate human data exist. It should not be used in pregnant women or those planning to become pregnant. If exposure occurs during pregnancy, the patient should be apprised of the potential hazard to the fetus.
No human data available. Enzalutamide and its active metabolite are likely excreted into human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 1 month after the last dose. M/P ratio is unknown.
It is unknown whether darolutamide or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment with NUBEQA and for at least 1 week after the final dose. The milk-to-plasma ratio (M/P ratio) is not available.
Enzalutamide is contraindicated in pregnancy; therefore, no dose adjustments are recommended. If exposure occurs, discontinue the drug and manage according to clinical judgment. Pregnancy induces metabolic changes (e.g., increased hepatic clearance, plasma volume expansion) that could theoretically reduce exposure, but no data exist to support a specific dose adjustment.
No dosing adjustment recommendations are available for use during pregnancy because NUBEQA is contraindicated in pregnant women. There are no clinical data regarding the pharmacokinetic changes in pregnancy, and no studies have evaluated the need for dose adjustment in this population. Therefore, no specific dose adjustments for pregnancy are provided.
Monitor for seizure risk, especially in patients with predisposing factors; enzalutamide may cause hypertension, so check blood pressure regularly; it significantly induces CYP3A4, reducing efficacy of oral contraceptives and other CYP3A4 substrates; use with caution in patients with history of cardiovascular disease; discontinue 5 half-lives before starting another antiandrogen.
NUBEQA (darolutamide) is a non-steroidal androgen receptor inhibitor with low blood-brain barrier penetration, reducing CNS side effects like falls and fractures. Monitor for cardiovascular events and hypertension; dose adjustment required in severe renal impairment (e GFR 15-29 m L/min) or moderate hepatic impairment (Child-Pugh B). Administer with food to enhance absorption. No dose adjustment for mild renal or hepatic impairment.
Take the capsules whole, with or without food, at the same time each day.,Do not crush, chew, or open the capsules.,Report any signs of seizure (e.g., convulsions, loss of consciousness) to your doctor immediately.,Enzalutamide may raise your blood pressure; have it checked regularly.,Use effective non-hormonal contraception during treatment and for 3 months after stopping; hormonal contraceptives may not work.,This drug may cause fatigue, falls, and fractures; avoid activities requiring alertness until you know how it affects you.,Notify your doctor if you experience chest pain, shortness of breath, or leg swelling.,Seek immediate medical attention for symptoms of posterior reversible encephalopathy syndrome (PRES): headache, confusion, visual disturbances.
Take NUBEQA with food at the same time each day.,Swallow tablets whole; do not crush, chew, or split.,Do not take with strong P-glycoprotein (P-gp) inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole).,Report unusual bleeding, bruising, or signs of bleeding (e.g., blood in urine or stool).,Use effective contraception during treatment and for 1 week after last dose if partner could become pregnant.,Inform your doctor if you have severe kidney or moderate liver problems.
"Rifaximin is a non-systemic antibiotic with minimal oral absorption (<0.4%), thus is not expected to significantly affect systemic drug metabolism. However, in vitro studies suggest rifaximin can induce the expression of CYP3A4, the major enzyme responsible for the metabolism of enzalutamide. Although clinical data are limited, coadministration could theoretically decrease enzalutamide exposure, reducing its efficacy in treating prostate cancer; conversely, the baseline description suggests an increase, but evidence is conflicting."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
"Enzalutamide, a potent androgen receptor inhibitor, significantly induces CYP3A4 and other drug-metabolizing enzymes. Dienogest, a progestin used in endometriosis and contraception, is primarily metabolized by CYP3A4. Coadministration leads to markedly reduced dienogest plasma concentrations, potentially diminishing its therapeutic efficacy in managing endometriosis symptoms or contraceptive effectiveness."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENZALUTAMIDE vs NUBEQA, answered by our medical review team.
ENZALUTAMIDE is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.. NUBEQA is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENZALUTAMIDE and NUBEQA depend on the specific clinical indication. These are both Androgen Receptor Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENZALUTAMIDE is: 160 mg orally once daily. The standard adult dose of NUBEQA is: 600 mg orally twice daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENZALUTAMIDE and NUBEQA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENZALUTAMIDE is classified as Category D/X. Enzalutamide is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibitor), there is a high risk of fetal harm, particularly male pseudohermaphrod. NUBEQA is classified as Category C. NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.